Compare PLX & KRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLX | KRMD |
|---|---|---|
| Founded | 1993 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.9M | 192.5M |
| IPO Year | 1996 | 2019 |
| Metric | PLX | KRMD |
|---|---|---|
| Price | $2.72 | $3.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.00 | $6.50 |
| AVG Volume (30 Days) | ★ 672.2K | 214.3K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $52,744,000.00 | $41,127,366.00 |
| Revenue This Year | $36.81 | $20.32 |
| Revenue Next Year | N/A | $17.37 |
| P/E Ratio | $10.19 | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $1.60 | $3.06 |
| 52 Week High | $3.19 | $6.61 |
| Indicator | PLX | KRMD |
|---|---|---|
| Relative Strength Index (RSI) | 55.19 | 40.46 |
| Support Level | $2.59 | $3.18 |
| Resistance Level | $2.75 | $3.43 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 42.87 | 53.75 |
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.